Nicox S.A. (LON:0RCQ)

Market Cap	24.88M
Revenue (ttm)	6.50M
Net Income (ttm)	-18.52M
Shares Out	n/a
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,070
Average Volume	63,824
Open	0.3540
Previous Close	0.3580
Day's Range	0.3540 - 0.3650
52-Week Range	0.2000 - 0.6500
Beta	0.89
RSI	45.07
Earnings Date	Sep 23, 2025

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RCQ

Financial Performance

In 2024, Nicox's revenue was 7.86 million, an increase of 13.84% compared to the previous year's 6.90 million. Losses were -22.39 million, 7.23% more than in 2023.

Financial numbers in EUR